Literature DB >> 9459667

[Hyperkinetic syndrome and behavioral disorders in street traffic: a case control pilot study].

N Beck1, A Warnke, H P Krüger, W Barglik.   

Abstract

In the present pilot study we addressed the question of whether young people diagnosed with attention deficit hyperactivity disorder (ADHD) as children violate traffic regulations and are involved in traffic accidents more frequently than those in a control group without previous psychiatric disorders. The subjects in the ADHD group tended to be involved in traffic accidents more frequently than those in the control group. Furthermore, they had a significantly higher rate of involvement in traffic accidents before getting their driver's license. The two groups did not differ in the number of traffic violations, alcohol consumption or various attitudes related to driving. Split attention and reactive endurance were assessed with a computer-aided program. The ADHD group partly did significantly worse than the control group. Deficits on such performance measures and a lack of cognitive control in traffic may therefore be mediating factors for being accident-prone in traffic. Regardless of which group subjects were in initially, those reporting severe ADHD symptoms at the time of the study tended to be at an increased risk of causing traffic accidents and of being involved in more than one accident.

Entities:  

Mesh:

Year:  1996        PMID: 9459667

Source DB:  PubMed          Journal:  Z Kinder Jugendpsychiatr Psychother        ISSN: 1422-4917


  2 in total

1.  Adolescents with attention deficit and hyperactivity disorder/learning disability and their proneness to accidents.

Authors:  Uzi Brook; Mona Boaz
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 1.967

Review 2.  Driving and attention deficit hyperactivity disorder.

Authors:  Anselm B M Fuermaier; Lara Tucha; Ben Lewis Evans; Janneke Koerts; Dick de Waard; Karel Brookhuis; Steffen Aschenbrenner; Johannes Thome; Klaus W Lange; Oliver Tucha
Journal:  J Neural Transm (Vienna)       Date:  2015-09-29       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.